Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 7/20 | 0.41 |
| ▸ | PDE4A | P27815 | 2/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.31 |
| ▸ | LDHB | P07195 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15713202 | 0.79 | AKR1B1 (0.35) | AKR1B1 | |
| SCHEMBL5589323 | 0.77 | AKR1B1 (0.35) | AKR1B1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19099662 | 0.75 | AKR1B1 (0.37) | AKR1B1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6236991 | 0.74 | MAPT (0.47) | TDP1MAPTCYP3A4 | |
| SCHEMBL9656615 | 0.74 | KDM4E (0.46) | AKR1B1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21508640 | 0.74 | AKR1B1 (0.39) | AKR1B1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5586599 | 0.72 | MAPT (0.32) | AKR1B1TDP1MAPTCYP3A4 | |
| SCHEMBL19730500 | 0.72 | LDHA (0.37) | AKR1B1TDP1MAPTCYP3A4LDHA | |
| SCHEMBL5589113 | 0.72 | LDHA (0.37) | AKR1B1TDP1MAPTCYP3A4LDHA | |
| SCHEMBL19998507 | 0.72 | LDHA (0.37) | AKR1B1TDP1MAPTCYP3A4LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247687-B2 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1521758-B1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | MLX, LOX, LMTK3 | AKR1B1 2038/4885PDE4A 4875/4885PDE4B 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.